UnaCom News- An Economic Round-Up


                                                                             30th July- 5th August



Sanofi starts stockpiling drugs due to uncertainty around Brexit.

Due to mounting uncertainty around the type of Brexit deal being reached, numerous drug companies have begun to take matters into their own hands. Depending on the arrangements reached, Brexit could cause massive disruption to the transport of the drugs between the UK and the EU. With border checks and delays disrupting the manufacturing and marketing process.As a result companies like French owned Sanofi have joined the ranks of AstraZeneca and MSD (Merck and co) in stockpiling medicines.
Sanofi a large producer of insulin and vaccines has created a 14 week supply starting from April 2019 an increase from its usual 10 week supply. These preparatory actions for a no deal outcome show that they are expecting problems and are taking actions to ensure that any disruptions does not affect patient safety and ensures there is a sufficient supply of their drugs in the UK market. (Guardian.co.uk 2018)


GSK Invests £228 million dollars into gene profiling group 23andme


GSK  will invest £228 million in  Google backed gene profiling group 23andme. The  four year collaboration between the two companies, will hopefully propel GSK to ‘Microsoft of the pharmaceutical industry’ as they stated decades ago (Guardian.co.uk) . GSK hopes to gain insights into gene data of 5 million users of 23andme, and thus be able to use this research for development of innovative medicines. GSK will have access to its drug database  and propriety statistical analysis to improve drug target discovery.R&D will improve target selection to allow precise medicines to be discovered and allow for more effective identification and recruitment of patients for clinical studies. (GSK.co.uk 2018)

Roche reports strong showing in the first half of 2018

Roche has reported strong performance in the first half of 2018. Group sales rose 7% to CHF (Swiss Francs)28.1 billion and core EPS grew 19%. EPS (earnings per share) tells how much money the company is making in profits per every outstanding share of stock. It tells how much money is flowing down to stockholders. The higher the EPS, the more money your share of stocks will be worth because investors are willing to pay more for higher profits. (Nasdaq.com 2018)
The rise in group sales by 7% can be down to recently launched medicines Ocrevus, a medicine used to treat two forms of multiple sclerosis, and cancer medicines Perjeta, Alecensa and Tecentriq. 
US sales increased by 15% led by Ocrevus, supported by demand from patients. A 27% increase in Perjeta occurred due to its use for patients after treatment with early breast cancer. 
In Europe (-8%) the success of Ocrevus and Perjeta offset declining sales of Rituxan/ MabThera. 
Roche CEO, Severin Schwan, commented on the strong results of the Pharmaceutical and Diagnostics Divisions and stated that Roche is ‘well on track to rejuvenate our portfolio’. They are increasing the outlook for the full year 2018 to mid single digits sale growth and core earnings per share to grow in the mid teen digits at constant exchange rates. (WorldPharmaNews.com 2018)


Almirall secures US Dermatology portfolio in $650 million deal 

Spanish company Almirall secured the dermatology portfolio of Allergan for $650 million dollars. With an upfront cash payment of $550 million and a potential earn out of up to $100 million payable in 2022 based on the performance of the portfolio. The deal covers the drugs such as Aczone and Tazorac in treatment of acne as well as the new, promising drug Seysara a treatment for moderate to severe acne vulgaris in patients 9 years old.  This acquisition secures Almiralls' position in the American dermatology market - the worlds largest market-

No comments:

Post a Comment

Coranavirus and its relationship with IP exclusivity

With the global shutdown that has occurred due to COVID-19, its presence has caused long-lasting effects in all aspects of our lives and t...